A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis-Targeting Chimeras Enhanced Immunotherapy.
Yaping WuXiaowei ChangGuizhu YangLi ChenQi WuJiamin GaoRan TianWenyun MuJohn Justin GoodingXin ChenShuyang SunPublished in: Advanced materials (Deerfield Beach, Fla.) (2023)
Although immunotherapy has revolutionized oncotherapy, only ≈15% of head and neck squamous cell carcinoma (HNSCC) patients benefit from the current therapies. An immunosuppressive tumor microenvironment (TME) and dysregulation of the polycomb ring finger oncogene BMI1 are potential reasons for the failure. Herein, to promote immunotherapeutic efficacy against HNSCC, an injectable nanocomposite hydrogel is developed with a polymer framework (PLGA-PEG-PLGA) that is loaded with both imiquimod encapsulated CaCO 3 nanoparticles (RC) and cancer cell membrane (CCM)-coated mesoporous silica nanoparticles containing a peptide-based proteolysis-targeting chimeras (PROTAC) for BMI1 and paclitaxel (PepM@PacC). Upon injection, this nanocomposite hydrogel undergoes in situ gelation, after which it degrades in the TME over time, releasing RC and PepM@PacC nanoparticles to respectively perform immunotherapy and chemotherapy. Specifically, the RC particles selectively manipulate tumor-associated macrophages and dendritic cells to activate a T-cell immune response, while CCM-mediated homologous targeting and endocytosis delivers the PepM@PacC particles into cancer cells, where endogenous glutathione promotes disulfide bond cleavage to release the PROTAC peptide for BMI1 degradation and frees the paclitaxel from the particle pores to elicit apoptosis meanwhile enhance immunotherapy. Thus, the nanocomposite hydrogel, which is designed to exploit multiple known vulnerabilities of HNSCC, succeeds in suppressing both growth and metastasis of HNSCC.
Keyphrases
- drug delivery
- cancer therapy
- reduced graphene oxide
- dendritic cells
- immune response
- body mass index
- drug release
- quantum dots
- hyaluronic acid
- end stage renal disease
- solid phase extraction
- carbon nanotubes
- tissue engineering
- wound healing
- weight gain
- ejection fraction
- newly diagnosed
- oxidative stress
- chronic kidney disease
- visible light
- papillary thyroid
- dna damage
- gold nanoparticles
- aqueous solution
- peritoneal dialysis
- highly efficient
- cell death
- dna repair
- prognostic factors
- patient reported outcomes
- toll like receptor
- regulatory t cells
- locally advanced
- squamous cell
- young adults
- lymph node metastasis
- radiation therapy
- high resolution
- pi k akt
- childhood cancer